Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-06-11 - Goldman Sachs Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.75 USD

Average target price

53.19 USD

Spread / Average Target

+27.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.94%	84.63B
ELI LILLY AND COMPANY	+41.68%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-6.81%	356B
MERCK & CO., INC.	+17.72%	326B
ABBVIE INC.	+5.75%	286B
ASTRAZENECA PLC	+17.66%	246B
ROCHE HOLDING AG	-3.48%	213B
NOVARTIS AG	+10.88%	213B
PFIZER, INC.	+1.73%	167B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:39:55 2024-06-05 EDT			5-day change	1st Jan Change
41 ^USD	-1.78%		+2.06%	-19.94%

03:53pm	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT
06-04	Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	MT

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	09:53am	MT
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	06-04	MT
Bristol Myers: positive results in liver cancer	06-04	CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	06-04	CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	06-03	MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	06-03	CI
Bristol Myers: presents advances in lung cancer	06-03	CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	06-03	CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02	RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	06-01	CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	05-30	MT
Bristol Myers: FDA approval for Breyanzi	05-30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	05-30	RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	05-30	CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	05-29	MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer	05-29	MT
Bristol Myers: new EC approval for Opdivo	05-29	CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine	05-29	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	05-28	MT
Bristol Myers: will present data on schizophrenia	05-27	CF
Bristol Myers: presents over 130 studies at ASCO	05-27	CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	05-23	MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	05-22	RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	05-22	MT